TrueMe review

TrueMe shows its prices up front and then undercuts them at checkout. It publishes sermorelin and NAD⁺ at $149 a month each, on the homepage, the shop and the product pages, with no intake form standing between you and the price — and one figure is stated to cover the medical intake, the provider review, the medication, temperature-controlled shipping, administration supplies and ongoing portal support, with no separate membership fee. Then the cart bills every 4 weeks. That is thirteen charges a year against a price marketed per month, so the real annual cost is a month's worth higher than the arithmetic implies. It also serves only six states.

TrueMe (TRUEMEHEALTH LLC, 4732 Sugar Grove Blvd, Stafford, Texas) is a cash-pay telehealth brand selling four products at published prices: GLP-1 (compounded semaglutide with added B vitamins) at $159/mo, GLP-1/GIP (compounded tirzepatide with added B vitamins) at $189/mo, NAD⁺ at $149/mo and sermorelin at $149/mo, each with a discounted three-month prepay alternative. Glutathione is described in its peptide-therapy copy without a published price. It states in its own footer that it partners with independent licensed physician networks including Strive, that medical care is delivered through the Telegra telehealth platform, and that TrueMe is not itself a state-licensed pharmacy or drug manufacturer.

Asynchronous and storefront-shaped, with prices visible before any intake — which is genuinely reader-friendly and rarer than it should be. Its FAQ states what a plan price includes in its own words: the medical intake and provider review, the prescribed medication if approved, temperature-controlled shipping where required, necessary administration supplies and ongoing provider support through the secure patient portal, with no separate membership fees. It also states that any charge is refunded if a provider decides treatment is not medically appropriate, which softens the biggest structural flaw — that you pay before the health questionnaire is complete, so approval is not settled at the moment you are charged. It carries a LegitScript-issued seal (ID 50205625) that links to LegitScript's own site, which is a real check rather than a copied badge. The gaps cluster around identity and consistency. No clinician or founder is named anywhere. The FAQ says the dispensing pharmacy may vary, while the returns policy names CarePoint Infusion Pharmacy at the company's own address. Its Terms name Georgia governing law while the arbitration clause on the same page applies California law. Its refund policy says it does not ship refrigerated products while the FAQ describes cold-chain shipping. And its homepage lists five service states while every treatment page lists six.

Transparent in presentation and misleading in cadence. Sermorelin and NAD⁺ are both $149 a month month-to-month, with a three-month option at $109 a month billed as a single upfront charge — and the site is clear that the three-month figure is one payment, not a lower monthly plan, which is more honest than most prepay presentations. The same structure runs across GLP-1 at $159 and GLP-1/GIP at $189. The catch is the billing cycle. The cart and checkout show "every 4 weeks" against every product, with the recurring total and first renewal date both stated on a 28-day cadence. Thirteen charges a year against a price marketed per month is roughly an extra 8% you will not find in any comparison table, and it is not disclosed next to the price. Before ordering, confirm two things in writing: whether your charge recurs every 28 days or every calendar month, and what the total annual cost is at that cadence. Also note the geography constraint, which is tight — six states, and its own site cannot agree on whether it is five or six.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. TrueMe states plainly on every treatment page that it is not a state-licensed pharmacy nor a drug manufacturer, and that medical care is provided by independent licensed healthcare providers through the Telegra platform with physician networks including Strive — which is a clearer separation of roles than most storefronts publish. The dispensing pharmacy is hedged as varying by treatment, location and licensing, though its returns address names CarePoint Infusion Pharmacy. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, sermorelin and NAD⁺ are not equivalent. Sermorelin is a GHRH analog that prompts your own pituitary to release growth hormone — a real, well-described mechanism with thin long-term human outcome data. Injected NAD⁺ has no controlled human outcome trials at all; the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears plasma quickly, and the forms with human data are the oral precursors NR and NMN, which raise a blood level rather than demonstrate a benefit. Injectable glutathione has essentially no controlled human outcome data. Individual results vary.